Review on cardioprotective strategies in the setting of chemotherapy-induced cardiotoxicity

Abstract Background Chemotherapy-induced cardiotoxicity represents a major challenge in the care of cancer patients, particularly with anthracyclines, HER2-directed therapies, and other cytotoxic agents. As cancer survival improves, preserving cardiovascular health has become increasingly important....

Full description

Bibliographic Details
Published in:	Cardio-Oncology
Main Authors:	Vinh Dao, Shray Amin, Thirumala Kammaripalle, Kenneth Manning
Format:	Article
Language:	English
Published:	BMC 2026-04-01
Subjects:	Chemotherapy-induced cardiotoxicity Cardio-oncology Dexrazoxane Beta-blockers ACE inhibitors ARBs
Online Access:	https://doi.org/10.1186/s40959-026-00480-4

Similar Items

Prevention strategy of cardiotoxicity in cancer chemotherapy
by: 韩尽斌, et al.
Published: (2018-02-01)

Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
by: Neha Bansal, et al.
Published: (2019-12-01)

Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis
by: Kyriakos Goulas, et al.
Published: (2023-07-01)

The Cardioprotective Effects of Empagliflozin with and Without ACE Inhibition in Chemotherapy-Induced Cardiotoxicity
by: Tim Rozovsky, et al.
Published: (2026-04-01)

Anthracycline-Induced Cardiotoxicity
by: Radomír Hrdina, et al.
Published: (2000-01-01)

Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice
by: Giuliana Ciappina, et al.
Published: (2025-09-01)

Cancer therapy-induced cardiotoxicity: Review and algorithmic approach toward evaluation
by: K Purkayastha, et al.
Published: (2017-01-01)

Treatment of left ventricular dysfunction during cancer therapy: a comprehensive review
by: Edgardo Kaplinsky, et al.
Published: (2026-04-01)

New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies
by: Oreste Lanza, et al.
Published: (2022-05-01)

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
by: Ariane V.S. Macedo, MD, MSc, et al.
Published: (2019-09-01)

Cardioprotection of cancer patients receiving cardiotoxic chemotherapy — current status
by: Anton K. Peresada, et al.
Published: (2024-01-01)

Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial
by: Eglė Čiburienė, et al.
Published: (2023-12-01)

Carvedilol Exerts Cardioprotective Effects Against Doxorubicin Toxicity via Autophagy Modulation and Energetics Restoration
by: Asma Boukhalfa, et al.
Published: (2026-05-01)

Nuclear imaging of chemotherapy-induced cardiotoxicity
by: A. A. Ansheles, et al.
Published: (2021-03-01)

Investigation of some chemotherapy drugs induce cardiotoxicity
by: Asia A. Mahdi, et al.
Published: (2025-08-01)

Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective
by: Sarah Dewilde, et al.
Published: (2020-02-01)

Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case
by: A. A. Avagimyan, et al.
Published: (2021-11-01)

Development of a Cardio-Oncology Service in Lithuania: Prediction, Prevention, Monitoring and Treatment of Cancer Treatment-Induced Cardiotoxicity
by: Eglė Čiburienė, et al.
Published: (2022-04-01)

Utilization of dexrazoxane in patients treated with doxorubicin: a retrospective, propensity matched analysis of cardiac function and toxicity
by: Zachary M. Neiman, et al.
Published: (2025-07-01)

The broad spectrum of cardiotoxicities from immunotherapies
by: Martina Iengo, et al.
Published: (2023-09-01)

Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know
by: Armando Ferrera, et al.
Published: (2023-05-01)

Cardiotoxicity and Chemotherapy—The Role of Precision Medicine
by: Thyla Viswanathan, et al.
Published: (2021-12-01)

Cardioprotective effect of thiotriazoline in cancer patients
by: A. V. Koltsov, et al.
Published: (2023-02-01)

Comparative study on the protective effect of dexrazoxane and blueberry extract against doxorubicin-induced cardiotoxicity in rats
by: Nourhan Ahmed Shaker, et al.
Published: (2025-09-01)

A review of cardioprotective effect of ginsenosides in chemotherapy-induced cardiotoxicity
by: Hadi Zare-Zardini, et al.
Published: (2024-12-01)

Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase
by: Anchit Bhagat, et al.
Published: (2022-08-01)

Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity
by: Dong-Woo Kang, et al.
Published: (2022-01-01)

Anticancer drugs and cardiotoxicity: the role of cardiomyocyte and non-cardiomyocyte cells
by: Chrysa Koukorava, et al.
Published: (2024-07-01)

Atrial fibrillation in a patient with lung cancer: a case report
by: E. Yu. Shupenina, et al.
Published: (2022-12-01)

Practical Approaches to Build and Sustain a Cardio-Oncology Clinic
by: Angeliki Chasouraki, et al.
Published: (2022-05-01)

Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients
by: Luigi Spadafora, et al.
Published: (2025-06-01)

NSTEMI and supraventricular tachycardia post-chemotherapy: a rare cardiotoxic complication
by: Eilham Elias Jobir, et al.
Published: (2026-04-01)

Demystifying the Relationship Between Metformin, AMPK, and Doxorubicin Cardiotoxicity
by: Manrose Singh, et al.
Published: (2022-01-01)

New opportunities for preclinical diagnostics of antitumor therapy cardiotoxicity: results of an observational study
by: Yu. A. Vasyuk, et al.
Published: (2025-08-01)

Potential Ameliorating Role of Spironolactone in Trastuzumab-induced Cardiotoxicity: A Narrative Review
by: Amir Ghabousian, et al.
Published: (2021-11-01)

Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy
by: Anthony F. Yu, et al.
Published: (2023-03-01)

Evolving field of cardio-oncology
by: Guo Li, et al.
Published: (2023-04-01)

Association between Statin Use and Chemotherapy-Induced Cardiotoxicity: A Meta-Analysis
by: Vikash Jaiswal, et al.
Published: (2024-03-01)

Electrophysiological mechanisms behind the differential cardiotoxicity of chemotherapeutic agents Bortezomib and Carfilzomib
by: Dario Melgari, et al.
Published: (2026-06-01)

Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications
by: Cecilia Kwok, et al.
Published: (2023-09-01)